Oral cavity and oropharyngeal squamous cell carcinomas (OSCC) constitute a major public health burden worldwide. Approximately 400,000 new cases of OSCC were diagnosed in 2002, and approximately 200,000 patients died of these cancers 1 . The major risk factors for OSCC are cigarette smoking, alcohol consumption, and betel quid chewing. The evidence for HPV as a potential etiologic agent in OSCC was first reported in 1983, when the presence of HPV antigen was shown in oral cancer specimens 2 . Subsequent publications showed an association between infection with high risk types of HPV and OSCC risk [3] [4] [5] [6] . Molecular and epidemiologic studies strongly suggest that HPV-positive OSCC comprise a distinctive disease entity that differs from HPV-negative OSCC in molecular, histopathologic and prognostic characteristics [7] [8] [9] [10] , with HPV-positive OSCC less frequently associated with p53 mutations, primarily located in the oropharynx, tending to be poorly differentiated and basaloid subtypes, and having a more favorable disease outcome. 7 . To understand the molecular mechanisms underlying these two entities of OSCC, we examined genome-wide gene expression profiles of HPV-positive and HPV-negative OSCC.
Materials and Methods.

Study population
Eligible cases were patients with first incident primary OSCC scheduled for surgical resection or biopsy between December 2003 and May 2006 at one of three University of Washington-affiliated medical centers in Seattle, WA. We were able to recruit 135 patients from among 184 eligible patients,. Among 135 consented patients, tissue could not be obtained from seven patients, and two patients had a final pathological diagnosis of dysplasia. These nine patients were excluded from the study.
Eligible controls were patients who had oral surgery for treatment of diseases other than cancer, such as obstructive sleep apnea, at the same institutions and during the same time period in which the OSCC cases were treated. In that time period, there were 45 eligible controls approached for participation by study staff, of whom 37 were recruited.
Each patient was interviewed using a structured questionnaire regarding demographic, medical, and lifestyle history, including tobacco and alcohol use. Data on tumor characteristics (site, stage) were obtained from medical records. Two cancer patients who enrolled in the study but did not consent to having their medical records reviewed were excluded from analysis. Thus, 124 cancer patients were included in this study. This research was conducted with written informed consent and institutional review board approval.
Tissue Collection
Tumor tissue was obtained at the time of resection from patients with primary OSCC prior to chemo/radiation therapy. Normal oral or oropharyngeal tissue was obtained from controls. One control provided two normal tissues and one cancer case had a large tumor that was divided into five pieces. Immediately after surgical removal, each tumor or normal tissue was soaked in RNALater (Applied Biosystems, Foster City, CA) for a minimum of 12 hours at 4 ° C and transferred to long term storage at -80 ° C prior to use.
DNA Microarray
The DNA and RNA from each specimen were simultaneously extracted using the TRIzol method (Invitrogen, Carlsbad, CA). To increase DNA purity, we modified the DNA extraction protocol to include the use of a "back extraction buffer" (4 M guanidine thiocyanate, 50 mM sodium citrate, and 1 M Tris, pH 8.0). RNA was further purified with the use of an RNeasy mini kit (Qiagen, Valencia, CA)
as per Affymetrix recommendations. For expression array analysis, 1.0 to 2.5 µg of total RNA was converted to double stranded cDNA using a GeneChip Expression 3'-Amplification One-cycle DNA Synthesis Kit (Affymetrix, Santa Clara, CA). The cDNA was purified and used in an in vitro transcription reaction to produce cRNA using the GeneChip Expression 3'-Amplification Reagents Kit (Affymetrix). The newly synthesized and biotin labeled cRNA was hybridized to a U133 2.0 Plus GeneChip (Affymetrix) and scanned using an Affymetrix GeneChip Scanner 3000 7G in the Fred
Hutchinson Cancer Research Center's Genomics Shared Resources as per Affymetrix protocols.
Quality Control (QC) of Microarray Results
We used the QC criteria specified by Affymetrix (http://www.affymetrix.com/support/downloads/manuals/data_analysis_fundamentals_manual.pdf) followed by the "affyQCReport" and "affyPLM" packages in Bioconductor (http://www.bioconductor.org) to search for poor quality GeneChips. These procedures identified seven GeneChips that did not pass QC tests (five from cancer patients and two from controls), and which were eliminated from further analyses. Thus 123 GeneChips from 119 cancer cases and 36
GeneChips from 35 controls were included in this analysis.
HPV Genotyping
We screened all samples for the presence of HPV DNA using a nested PCR based protocol
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. All samples that had a positive PCR result and about 40% of the samples that had a negative result were tested for HPV DNA presence using the LINEAR ARRAY HPV Genotyping 
Data Analysis
Tumors were classified according to site as follows: oral cavity (including tongue, buccal mucosa, gingival, hard palate, retromolar trigone and floor of mouth) vs. oropharynx (including tonsils, soft palate, uvula, oropharynx and base of tongue).
Gene expression values for the ~54,000 probe sets were first extracted from probe intensity values (CEL files) using the gcRMA algorithm. We then eliminated the probe sets that either showed no variation across the samples (inter-quartile range less than 0.1 on log2 scale) or that were expressed at very low magnitude (the maximum of the expression value across the samples is less than 3 on log 2 scale). These exclusions helped to limit the number of statistical tests applied when detecting differences between HPV-positive and HPV-negative tumors. After these two filtering processes, ~21,000 probe sets remained for further analysis.
Statistical tests were carried out to compare HPV-positive and HPV-negative OSCC using a regression framework implemented in GenePlus software (http://www.enodar.com/). To control for the type I error rate, we chose to declare a particular group of genes either "upregulated/overexpressed" or "downregulated/underexpressed" based on a pre-specified Number of False Discoveries (NFD)
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The choice of NFD, with an appropriate account for the number of genes under investigation (J), dictates the threshold for individual gene-specific p-values as NFD/J.
To determine whether the probe sets identified in the above analysis were up-or downregulated when compared to normal oral tissue, for each probe set we compared the mean expression values of each cancer group with those of controls using linear regression, calculating a robust estimator of variance, and accounting for the fact that multiple samples were tested for some subjects. The probe sets were then placed in order by ascending p-value, and a cutoff of 0.05 was chosen to indicate significant differences in expression.
The functional roles of the genes differentially expressed between HPV-positive and HPVnegative OSCC were assessed through the use of Ingenuity Pathways Analysis, IPA 5.0 (Ingenuity® Systems, www.ingenuity.com). The function analysis identified the biological functions by performing
Fischer's exact tests to test the null hypothesis that the set of differentially expressed genes were not representative of each biological function.
Results
Patient characteristics
The characteristics of the study population overall and by HPV status are presented in Table   1 . The cases were more likely to be older and to be current smokers, when compared with controls.
More cases presented with oral cavity tumors than oropharyngeal tumors. 
HPV detection in OSCC and
Genome-wide comparison between HPV-positive and HPV-negative OSCC
We used NFD = 1 as a selection criteria. This means that we control the number of false positive gene in the discover gene list to be fewer than 1. We did not find a significant difference in gene expression between HPV-positive and HPV-negative OSCC. When we analyzed oral cavity cancers and oropharyngeal cancers separately, we found no significant difference in gene expression between HPV-positive oral cavity cancers and HPV-negative oral cavity cancers, but we found 446 probe sets (Supplement 1, please see online version of manuscript) differentially expressed in HPVpositive oropharyngeal cancers compared to HPV-negative oropharyngeal cancers. This means that one probe set among 446 probe sets could be a false positive finding, corresponding to a false discovery rate (FDR) of 0.2%. The molecular and cellular functions of these genes that had the lowest p-values from the Ingenuity Pathways Analysis, IPA 5.0 were DNA replication, DNA recombination, DNA repair, and cell cycle ( Table 2) .
Comparisons to controls
In order to determine which, if any, of these 446 probe sets were up-or downregulated when compared to normal oral tissue, we compared HPV-positive oropharyngeal cancers and HPV- Table 3 . A complete list of the 299 differentially expressed probe sets is in Supplement 2 (please see online version of manuscript).
When comparing HPV-negative oropharyngeal cancers to HPV-negative oropharyngeal controls using these 446 probe sets, we found 79 upregulated probe sets and 122 downregulated probe sets. Table 4 lists the top 50 probe sets from this analysis. The list of 201 probe sets is shown in Supplement 3 (please see online version of manuscript).
There were 21 probe sets that were upregulated in HPV-positive oropharyngeal cancers but downregulated in HPV-negative oropharyngeal cancers, and four were downregulated in HPVpositive oropharyngeal cancers but upregulated in HPV-negative oropharyngeal cancers (Table 5) .
Comment
Human Papillomaviruses (HPV) are small DNA viruses that are known to be associated with a subset of OSCC. We found significant differences in gene expression on the genome-wide level between HPV-positive and HPV-negative oropharyngeal cancers, but not in oral cavity cancers. That our results depend on tumor site is consistent with the large body of evidence that HPV are more frequently detected in, and more strongly associated with, the development of oropharyngeal cancers than cancers in other head and neck sites STMN1, encodes stathmin, a protein involved in the regulation of microtubules. Two studies have shown that stathmin overexpression decreases sensitivity to paclitaxel in vitro 19, 20 . P53
regulates the G2/M check point by reducing expression of stathmin 21 . We found upregulation of STMN1 in HPV-positive oropharyngeal cancers. We speculate that inactivation of p53 by high-risk HPV E6 may cause increased expression of stathmin, resulting in greater resistance to paclitaxel compared to HPV-negative oropharyngeal cancers. Further study is needed to confirm this.
Radiation is a common treatment choice for oropharyngeal cancer, because of the morbidity associated with surgical resection. Torres-Roca et al. demonstrated that radiosensitive cell lines had higher expression of RBBP4 than radioresistant cell lines, and transfection of RBBP4 into cell lines induced radiosensitization of these cell lines 22 . We found upregulation of RBBP4 in HPV-positive oropharyngeal cancers. It would be interesting for future study to examine whether HPV-positive oropharyngeal cancers are more sensitive to radiation than HPV-negative oropharyngeal cancers.
Although the association between HPV infection and oropharyngeal cancer is well established, the clinical benefit of testing HPV in oropharyngeal cancer patients has not been established. Our results suggest the possibility of using HPV status for selecting personalized therapy for these patients. To translate these findings to patient management, clinical trials to evaluate the efficacy of cisplatin, 5-FU, paclitaxel, or radiation in the treatment of oropharyngeal cancers based on their HPV status are clearly warranted.
To the best of our knowledge, two previous studies have compared genome-wide gene expression between HPV-negative and HPV-positive HNSCC directly, using the same Affymetrix chip as the current study 23, 24 . Although both our and Martinez's studies focused on oropharyngeal tumors, our much larger sample size would be expected to detect larger numbers of differentially expressed genes.
Our study was limited by the small number of study subjects, particularly for comparisons among oropharyngeal cancer patients. With only eight HPV-negative oropharyngeal cancers, it was not feasible to include cigarette smoking, sex, and age as covariates when we compared genomewide gene expression between the HPV-positive and HPV-negative oropharyngeal tumors.
In conclusion, we found differences in gene expression in HPV-positive and HPV-negative oropharyngeal cancers. These differences suggest that 1) HPV-positive oropharyngeal cancers may be more resistant to 5-FU and paclitaxel than HPV-negative oropharyngeal cancers, 2) cisplatin may CDKN2A, LIG1, MCM6, CDT1, PTTG1, PARP2, SMC4, CDC7, DDB2, SASS6,  XRCC1, SP1, UBE2B, STK24, ZWINT, KIFC1, E2F2, ASF1B, NUSAP1,  CCNE2, ESPL1, TOPBP, POLE2, The bold fonts denote genes that were upregulated in HPV-positive compared to HPV-negative oropharyngeal cancer. 
